Lifecore Biomedical, Inc. \De\ (LFCR) Net Income towards Common Stockholders (2010 - 2025)

Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$2.0 million for Q2 2025.

• In Q2 2025, Net Income towards Common Stockholders rose 71.1% year-over-year to -$2.0 million; the TTM figure through May 2025 stood at -$42.6 million (down 273.15% YoY), while the FY2025 annual figure was -$44.4 million, down 469.26% from the prior year.
• Net Income towards Common Stockholders for Q2 2025 stood at -$2.0 million, up from -$15.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $15.6 million in Q1 2024, with the low at -$51.6 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$4.3 million (2021), against an average of -$9.2 million.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders tumbled 2376.79% in 2022, then soared 494.4% in 2023.
• Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders stood at -$46.0 million in 2021, then soared by 92.17% to -$3.6 million in 2022, then jumped by 494.4% to $14.2 million in 2023, then slumped by 161.21% to -$8.7 million in 2024, then surged by 76.48% to -$2.0 million in 2025.
• Business Quant data shows LFCR's Net Income towards Common Stockholders at -$2.0 million in Q2 2025, -$15.7 million in Q1 2025, and -$8.7 million in Q4 2024.